Pharmacokinetics of Piroxantrone in a Phase I Trial of Piroxantrone and Granulocyte-Colony Stimulating Factor

Stacey L. Berg, Frank M. Balis, David G. Poplack, Joyce A. O'Shaughnessy, Kenneth H. Cowan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Piroxantrone is an anthrapyrazole derivative with broad antitumor activity in vitro. In previous phase I trials, the dose-limiting toxicity of this agent was myelosuppression. Therefore, a phase I and pharmacokinetic study of a 1-h infusion of piroxantrone in combination with granulocyte-colony stimulating factor was conducted. In this article, we report the results of the pharmacokinetic analysis. Thirty-seven patients were studied over a dosage range of 150 to 555 mg/m2. The plasma elimination of piroxantrone was biexponential with a mean (SD) t1/2a of 3.2 2.7 min and a mean (SD) tm of 82 92 min. Clearance was 840 230 ml/min/m2. A limited sampling strategy was developed to allow the estimation of total drug exposure (area under the plasma concentration-time curve) from the plasma piroxantrone concentrations at 30, 60, and 120 min after the start of the infusion. The pharmacokinetic behavior of a presumed piroxantrone metabolite not previously declined in plasma was also characterized. Based on in vitro cytotoxicity studies with partially purified extract of this compound, we do not believe that it contributes to the antitumor effects of piroxantrone at the concentrations observed in plasma. Finally, piroxantrone elimination was linear over the nearly 4-fold dose range studied, indicating that when dose adjustments are made, systemic drug exposure will remain predictable.

Original languageEnglish (US)
Pages (from-to)2587-2590
Number of pages4
JournalCancer Research
Volume53
Issue number11
StatePublished - Jun 1993

Fingerprint

piroxantrone
Granulocyte Colony-Stimulating Factor
Pharmacokinetics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Berg, S. L., Balis, F. M., Poplack, D. G., O'Shaughnessy, J. A., & Cowan, K. H. (1993). Pharmacokinetics of Piroxantrone in a Phase I Trial of Piroxantrone and Granulocyte-Colony Stimulating Factor. Cancer Research, 53(11), 2587-2590.

Pharmacokinetics of Piroxantrone in a Phase I Trial of Piroxantrone and Granulocyte-Colony Stimulating Factor. / Berg, Stacey L.; Balis, Frank M.; Poplack, David G.; O'Shaughnessy, Joyce A.; Cowan, Kenneth H.

In: Cancer Research, Vol. 53, No. 11, 06.1993, p. 2587-2590.

Research output: Contribution to journalArticle

Berg, SL, Balis, FM, Poplack, DG, O'Shaughnessy, JA & Cowan, KH 1993, 'Pharmacokinetics of Piroxantrone in a Phase I Trial of Piroxantrone and Granulocyte-Colony Stimulating Factor', Cancer Research, vol. 53, no. 11, pp. 2587-2590.
Berg, Stacey L. ; Balis, Frank M. ; Poplack, David G. ; O'Shaughnessy, Joyce A. ; Cowan, Kenneth H. / Pharmacokinetics of Piroxantrone in a Phase I Trial of Piroxantrone and Granulocyte-Colony Stimulating Factor. In: Cancer Research. 1993 ; Vol. 53, No. 11. pp. 2587-2590.
@article{e5ae7b5e1ce6490aa5987086cb9d5a8d,
title = "Pharmacokinetics of Piroxantrone in a Phase I Trial of Piroxantrone and Granulocyte-Colony Stimulating Factor",
abstract = "Piroxantrone is an anthrapyrazole derivative with broad antitumor activity in vitro. In previous phase I trials, the dose-limiting toxicity of this agent was myelosuppression. Therefore, a phase I and pharmacokinetic study of a 1-h infusion of piroxantrone in combination with granulocyte-colony stimulating factor was conducted. In this article, we report the results of the pharmacokinetic analysis. Thirty-seven patients were studied over a dosage range of 150 to 555 mg/m2. The plasma elimination of piroxantrone was biexponential with a mean (SD) t1/2a of 3.2 2.7 min and a mean (SD) tm of 82 92 min. Clearance was 840 230 ml/min/m2. A limited sampling strategy was developed to allow the estimation of total drug exposure (area under the plasma concentration-time curve) from the plasma piroxantrone concentrations at 30, 60, and 120 min after the start of the infusion. The pharmacokinetic behavior of a presumed piroxantrone metabolite not previously declined in plasma was also characterized. Based on in vitro cytotoxicity studies with partially purified extract of this compound, we do not believe that it contributes to the antitumor effects of piroxantrone at the concentrations observed in plasma. Finally, piroxantrone elimination was linear over the nearly 4-fold dose range studied, indicating that when dose adjustments are made, systemic drug exposure will remain predictable.",
author = "Berg, {Stacey L.} and Balis, {Frank M.} and Poplack, {David G.} and O'Shaughnessy, {Joyce A.} and Cowan, {Kenneth H.}",
year = "1993",
month = "6",
language = "English (US)",
volume = "53",
pages = "2587--2590",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of Piroxantrone in a Phase I Trial of Piroxantrone and Granulocyte-Colony Stimulating Factor

AU - Berg, Stacey L.

AU - Balis, Frank M.

AU - Poplack, David G.

AU - O'Shaughnessy, Joyce A.

AU - Cowan, Kenneth H.

PY - 1993/6

Y1 - 1993/6

N2 - Piroxantrone is an anthrapyrazole derivative with broad antitumor activity in vitro. In previous phase I trials, the dose-limiting toxicity of this agent was myelosuppression. Therefore, a phase I and pharmacokinetic study of a 1-h infusion of piroxantrone in combination with granulocyte-colony stimulating factor was conducted. In this article, we report the results of the pharmacokinetic analysis. Thirty-seven patients were studied over a dosage range of 150 to 555 mg/m2. The plasma elimination of piroxantrone was biexponential with a mean (SD) t1/2a of 3.2 2.7 min and a mean (SD) tm of 82 92 min. Clearance was 840 230 ml/min/m2. A limited sampling strategy was developed to allow the estimation of total drug exposure (area under the plasma concentration-time curve) from the plasma piroxantrone concentrations at 30, 60, and 120 min after the start of the infusion. The pharmacokinetic behavior of a presumed piroxantrone metabolite not previously declined in plasma was also characterized. Based on in vitro cytotoxicity studies with partially purified extract of this compound, we do not believe that it contributes to the antitumor effects of piroxantrone at the concentrations observed in plasma. Finally, piroxantrone elimination was linear over the nearly 4-fold dose range studied, indicating that when dose adjustments are made, systemic drug exposure will remain predictable.

AB - Piroxantrone is an anthrapyrazole derivative with broad antitumor activity in vitro. In previous phase I trials, the dose-limiting toxicity of this agent was myelosuppression. Therefore, a phase I and pharmacokinetic study of a 1-h infusion of piroxantrone in combination with granulocyte-colony stimulating factor was conducted. In this article, we report the results of the pharmacokinetic analysis. Thirty-seven patients were studied over a dosage range of 150 to 555 mg/m2. The plasma elimination of piroxantrone was biexponential with a mean (SD) t1/2a of 3.2 2.7 min and a mean (SD) tm of 82 92 min. Clearance was 840 230 ml/min/m2. A limited sampling strategy was developed to allow the estimation of total drug exposure (area under the plasma concentration-time curve) from the plasma piroxantrone concentrations at 30, 60, and 120 min after the start of the infusion. The pharmacokinetic behavior of a presumed piroxantrone metabolite not previously declined in plasma was also characterized. Based on in vitro cytotoxicity studies with partially purified extract of this compound, we do not believe that it contributes to the antitumor effects of piroxantrone at the concentrations observed in plasma. Finally, piroxantrone elimination was linear over the nearly 4-fold dose range studied, indicating that when dose adjustments are made, systemic drug exposure will remain predictable.

UR - http://www.scopus.com/inward/record.url?scp=0027207370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027207370&partnerID=8YFLogxK

M3 - Article

C2 - 7684320

AN - SCOPUS:0027207370

VL - 53

SP - 2587

EP - 2590

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 11

ER -